Stockreport

Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) [Seeking Alpha]

Hims & Hers Health, Inc. Class A  (HIMS) 
PDF GLP-1s account for roughly 25% of HIMS revenue; losing this segment threatens growth and has triggered a 60% stock drawdown. Despite management's $6.5B 2030 target, l [Read more]